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ess: hkunst@doctors.orSummary Tuberculosis (TB) is a major cause of morbidity and mortality
worldwide. TB control programmes need improvement in the diagnosis of latent
TB infection. The tuberculin skin test (TST) is far from a ‘gold’ standard as it often
gives false results. Interferon-gamma assays are newly available tests to detect
latent TB infection, but they are currently not routinely used. They are based on
immune responses to purified protein derivative (PPD) or to region of difference 1
(RD1) specific antigens. Assays based on RD-1 specific antigens perform better than
both PPD based assays and TST. They correlate with TB exposure and are less likely to
give false results in non-tuberculous mycobacterial disease, Bacille Calmette-Guerin
(BCG) vaccination and immunosuppression. More accurate diagnosis of latent TB
infection with RD-1 specific antigen based interferon-gamma assays may allow
targeting of chemoprophylaxis to reduce the burden of active TB while decreasing
wastage of health care resources due to false results associated with TST. However,
further research and development is required to verify that new tests can predict
the risk of later development of active TB and to make it feasible to perform these
tests in a reproducible fashion at low cost, particularly in developing countries.
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One-third of the world’s population has latent
tuberculosis (TB) infection.1 This develops into
active disease in 5–10% of cases and annually 2
million people die from TB.2 Diagnosing people with
latent TB infection is important for control of the
disease. World Health Organisation’s (WHO) ‘‘global
plan to stop tuberculosis’’ intends to improve
diagnostic tests and to make them available for
use in high TB prevalence countries2 so that active
disease can be prevented by chemoprophylaxis.
Testing should be of sufficiently high accuracy to
prevent the unwanted consequences of false
results. For example, false-positive results can
lead to inappropriate initiation of chemoprophy-
laxis with potential toxic side-effects, while false-
negative results can lead to inappropriate non-use
of chemoprophylaxis with progression to active TB.
Both lead to unnecessary morbidity and use of
health care resources.
Mycobacterium tuberculosis is an intracellular
pathogen, which is difficult to recover from
infected subjects and humoral responses in TB
infection are weak.3 These factors have resulted in
difficulties when developing useful microbiological
and serological tests. Tuberculin skin test (TST)
remains the most commonly used test despite being
insufficiently accurate. Interferon-gamma assays
based on immune responses to purified protein
derivative (PPD) were first developed to detectFigure 1 Inoculation and interpretation of Tuberculin skin
syringe and needle; (b) measurement of skin induration 48–7latent TB infection. Recently more specific, region
of difference 1 (RD-1) based antigen assays have
become available. Several studies have been
conducted on comparing whole blood enzyme-
linked immunosorbent assay (ELISA) and enzyme-
linked immunospot (ELISPOT) assay with TST, which
have recently been reviewed.4–6 What are the
characteristics of these new tests and what is their
comparative value vis-a-vis traditional tests?Tuberculin skin test
TST is currently the standard tool to detect latent
TB infection, though it is far from a ‘gold’ standard.
TST is based on the detection of delayed-type
hypersensitivity to PPD, a mixture of antigens
shared by several mycobacteria that gives rise to
a skin reaction. Two visits are required for the test,
one for PPD inoculation (the Mantoux technique
uses intracutaneous injection by needle and syr-
inge) and another after 48–72 h for interpretation
of the result based on the size of the skin reaction
(Fig. 1).
TST is a simple test with low material costs and
can be performed without the need for a specialist
laboratory. This is important in high burden,
resource-limited countries where even quality
sputum microscopy may be difficult to access. TST
has been extensively used in resource-limited
settings for epidemiological field surveys on annualtest. (a) Inoculation of purified protein derivative using
2 h after inoculation. Source: www.phppo.cdc.gov.
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numbers of healthy children and conducting surveys
with a skin test is relatively straight forward.
Several longitudinal studies have demonstrated a
positive association between TST response and
subsequent risk of active TB.9,10 Randomized trials
have shown that treatment of latent infection,
diagnosed on the basis of positive TST, reduces the
risk of active TB. This experimental evidence has
lead to the policy of tuberculin testing and
treatment of latent TB infection.11–13
Difficulties in test administration and interpreta-
tion often lead to false results. There are many
practical difficulties in conducting TST. The second
of the two visits might pose a compliance problem
for people who live in remote settings and in some
patient groups, e.g. in urban human immunodefi-
ciency virus (HIV) clinics return rates are low.14 The
inoculation may induce a painful skin inflammation
sometimes with induration15 and with scarring at
the injection site, which may be unacceptable to
certain population groups. The test might not be
possible in individuals with skin disorders.
Dose of PPD, method of application and criteria
for interpretation vary between countries. Weak
PPD doses increase the likelihood of false-negative
results and strong doses increase the likelihood of
false-positive results. A 1.5mm difference of
reaction size may be seen when a 10 TU dose is
compared to 5 TU.16 The technique for inoculating
PPD doses may cause false results.17 Different tests
are available e.g. Heaf test, used in the UK, and
Mantoux test, used in most other countries. The
Heaf test, however, has been recently discontinued
in the UK, since small metal fragments were found
in the test site following use of Heaf test heads.18
Different cut-offs are used for positivity of TST, as
there is no general consensus on this issue. Criteria
of 5, 10 or 15mm for skin reaction have been
recommended depending on the clinical situa-
tion.11 There can be false TST results from operator
variability in both inoculation and reading of the
test.19 Digit preference e.g. rounding measures of
TST induration to the nearest multiple of 5mm and
interpretation bias can significantly affect TST
results.20
There are many reasons for false-positive TST
results (Table 2). PPD contains a poorly defined
mixture of mycobacterial antigens. Because anti-
gens are shared with other mycobacteria, tubercu-
lin reactivity leading to a positive TST can result
from Bacille Calmette-Guerin (BCG) vaccination
with a live attenuated mycobacterial strain derived
from M. bovis or from exposure to non-tuberculous
mycobacteria.21–24 Whereas in developed countries
BCG vaccination is not always routine, in develop-ing countries it is generally included in the
immunisation scheme and is usually given at birth
or in infancy. The effect of BCG vaccination on TST
can persist as long as 15 years after vaccination.17
The degree of BCG induced delayed-type hyper-
sensitivity varies with country, timing of vaccina-
tion, time elapsed since vaccination and whether
vaccination is repeated.22,25,26 There is consider-
able loss of hypersensitivity over time in several
subtropical and tropical countries as studies in
Uganda, India, Malawi, Sri Lanka, the Gambia and
the Solomon Islands have shown.22,27–32 Reaction to
TST in cases of BCG vaccination tends to be small,
however this is not always consistent.11
Specificity problems of PPD can be addressed by
simultaneous skin testing with M. tuberculosis PPD
and sensitins, which are PPD-like products derived
from non-tuberculous mycobacteria. This approach
can help to discriminate patients with TB from
those who are infected with M. avium com-
plex.33–35 Repeated TST’s may induce booster
responses leading to false-positive results.36 Energy
associated with HIV infection, disseminated TB or
immunosuppression due to haemodialysis, trans-
plantation or medication can give rise to false-
negative reactions.17,37,38
There have been many responses to the above
problems, none of which are ideal. Some countries
have stopped using BCG vaccination, since preven-
tion of adult tuberculosis with chemoprophylaxis
may be superior than using BCG vaccination.
However in view of the persistent increase of TB
in the UK compared to other European countries,
BCG vaccination is still continued.Interferon-gamma assays
Interferon-gamma assays have been developed as
tests to replace TST. They operate on a T-cell based
approach as TB infection evokes a strong T-helper 1
type cell-mediated immune response.39 Release of
interferon-gamma from M. tuberculosis specific
T-cells is used as a marker of infection. In vitro
studies of interferon-gamma production in response
to mycobacterial antigens can be used to detect
latent TB infection.40 The antigens used to illicit an
interferon-gamma response define the main types
of existing commercial tests: assays based on PPD
and those based on RD-1 specific antigens (Figs. 2
and 3). Three commercial interferon-gamma assays
have been developed, the QuantiFERON-TB assay
(Cellestis Limited, Carnegie, Victoria, Australia),
the T SPOT-TB assay (Oxford Immunotec, Oxford,
UK) and the Quantiferon Gold assay (Cellestis
Limited, Carnegie, Victoria, Australia).
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Figure 3 Principle of whole blood interferon-gamma assay ELISA. (a) Aliquots of undiluted whole blood are taken; (b)
antigens (PPD, ESAT-6, CFP10) are added and incubated overnight; (c) antigen-specific T-cells produce interferon-
gamma; (d) plasma is harvested and incubated in ELISA; (e) bound interferon-gamma is equivalent to colour
development; (f) Interferon-gamma is measured as IU/ml. Source: Adapted from manufacturer’s websites.
Figure 2 Principle of ELISPOT. (a) Microtiter plate wells are coated with monoclonal antibodies. T-cells secreting
interferon-gamma are added and incubated in the presence of tuberculosis antigens; (b) interferon-gamma is captured
by monoclonal antibodies; (c) conjugated second antibody is added to interferon-gamma followed by incubation and
washing of wells; (d) substrate is added and after colour change, spots can be counted; (e) spots in well correspond to
T-cells that have released interferon-gamma. Source: Adapted from manufacturer’s websites.
New technologies for tuberculosis diagnosis 2101The interferon-gamma tests have several advan-
tages over TST (Tables 1 and 2). They involve having
a blood test at a single visit and a return visit might
not be needed in some settings depending on the
test result. Patients may need to come back to
obtain the result and counselling about the
implications of the results in other settings.
Automated testing has the advantage of reducingreader bias as interpretation is objective. A booster
phenomenon does not occur and therefore screen-
ing of people who are repeatedly exposed to TB
(e.g. health care workers) becomes feasible and
these tests should prove a better marker of latent
TB infection than TST.41
Interferon-gamma assays also have some limita-
tions: The need to perform a blood test might not
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Table 1 Characteristics of tests for latent tuberculosis infection with regard to test administration.
Tuberculin skin test Interferon-gamma assays
Patient visit Two visits are required, one for
administration and one for
interpretation
Only one visit may be required, return
visit not always necessary in certain
settings
Laboratory No laboratory required, easy
administration
Laboratory and experience with assay
required
Reagents Reagents not standardised and vary
between countries
Reagents not standardised, several
assays available within one country
Site of test Skin test may cause inflammation and
scarring
Blood test required
Contraindicated in certain skin
conditions
Patient acceptability Painful on skin site, may not be
acceptable to some patient groups
Obtaining blood sample may not be
acceptable to some patient groups
especially children
Operator variability Operator variability in inoculation and
reading of test, false results may arise
due to improper placement or wrong
measurements
No reader bias, reduced risk of
misclassification
Effect of repeated
testing
Repeated tests can cause booster
responses
No booster response
Cost Cheap test Expensive test
Time of test 48–72 h 24 h or longer depending on resources
Abbreviations: PPD ¼ purified protein derivative, ESAT ¼early secretory antigen target, CFP ¼ culture filtrate protein.
Table 2 False results among tests for latent tuberculosis infection.
Tuberculin skin test Interferon-gamma assays
based on PPD
Interferon-gamma assays
based on RD1 specific
antigens
Use in patients with
BCG vaccination
False-positive due to BCG
vaccination
Likely less false-positive
due to BCG vaccination
Potentially even less
false-positive due to BCG
vaccination
Effect of non-
tuberculous
mycobacteria on
interpretation of test
False-positive due to
exposure to non-
tuberculous mycobacteria
Whole blood ELISA
discriminates between M.
avium and M.
tuberculosis, however not
other non-tuberculous
mycobacteria
Discriminates between
many non-tuberculous
mycobacteria however
not M. kansasii, M.
szulgai, M. marinum,
M.gastrii and M.
flavescens
Use in patients with
immuno-suppression
(e.g. HIV infection)
False-negative due to
anergy secondary to
immunosuppression
Possibly less false-
negative due to anergy
Potentially even less
false-negative due to
anergy (limited data
available)
Abbreviations: PPD ¼ purified protein derivative, ESAT ¼early secretory antigen target, CFP ¼ culture filtrate protein,
BCG ¼ Bacille Calmette-Guerin, HIV ¼ human immuno-deficiency virus.
H. Kunst2102be desirable in certain patient groups especially
children. The blood often needs to be processed
within 12 h after collection and laboratories need
to gain expertise in technology like isolation ofmononuclear cells.37 Although some laboratories in
developing countries have been run these tests
with simple equipment like centrifuge, incubator
and microscope,3 interferon-gamma assays are
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expensive and require at least a basic laboratory.
There are no reports of longitudinal studies showing
an association between positive interferon-gamma
response and subsequent risk of active TB. There is
also lack of evidence, whether withholding treat-
ment for latent TB infection based on a positive
TST, but negative interferon-gamma response is
safe.
Interferon-gamma assays based on PPD
The whole blood interferon-gamma ELISA, the
Quantiferon TB test42 was the first commercially
available test. Although it is inferior to RD1 specific
antigen based assays it is of relevance to mention
since many countries have used this whole blood
ELISA. This assay measures interferon-gamma pro-
duction with ELISA, after in vitro stimulation of
whole blood cells with PPD from M. tuberculosis
and control antigens.43,44 It is able to discriminate
between M. tuberculosis and M. avium intracellu-
lare complex infection.45 It responds to multiple
antigens spontaneously.43,46–48 It does not boost
anamnestic immune responses.48 Moreover the
whole blood ELISA interferon-gamma assay is
comparable with the TST in its ability to detect
latent TB infection.43,44,47 Disadvantages of a PPD-
based assay such as the whole blood ELISA is, that it
can give false-positive results in BCG vaccinated
people and that it does not discriminate between
most of the non-tuberculous mycobacteria and M.
tuberculosis.43,49–51 Tuberculin reactivity seems to
be more detectable by the whole blood interferon-
gamma assay than by TST in HIV infection, however
studies have shown conflicting results and it is not
clear if the whole blood ELISA is superior than
TST.52–54
Interferon-gamma assays based on RD-1
specific antigens
Interferon-gamma assay based on RD-1 specific
antigens, early secretory antigen target 6 (ESAT-6)
and culture filtrate protein 10 (CFP-10), can over-
come some of the above disadvantages. Compara-
tive genomics has identified several genetic regions
in M. tuberculosis and M. bovis that are deleted in
all tested BCG strains.55 The identified region, the
so-called region of difference 1 (RD1) region, is
present in M. kansasii, M. szulgai and M. mar-
inum56,57 however it is also encountered in rarer
mycobacteria such as M. flavescens and M. gastrii.
Proteins encoded in these regions have formed the
basis of new specific T-cell-based blood tests thatdo not cross-react with BCG, but only two antigens,
ESAT-6 and CFP 10 have been studied in detail in
humans.58 ESAT-6 is a secreted antigen that is
expressed in M. tuberculosis complex (M. tubercu-
losis, M. bovis, and M. africanum), but it is
compared to PPD absent from BCG and many non-
tuberculous mycobacteria.56,59 ESAT-6 and CFP-10
share the same messenger RNA transcript, which
suggest that CFP-10 and ESAT-6 may interact with
one another and serve a common function in
detection of M. tuberculosis.60 All stimulated
T-lymphocytes secrete interferon-gamma, but
ESAT-6 and CFP-10 assays can only detect inter-
feron-gamma secreted from T-lymphocytes pro-
duced as a result of exposure to ESAT-6 and CFP-
10 antigen. In vivo and in vitro experiments have
shown that the combination of ESAT-6 and CFP-10
has a higher sensitivity and specificity than PPD in
diagnosis of TB infection.49–51
There are two commercial assays available
incorporating the two RD1-based antigens ESAT-6
and CFP-10. The T SPOT-TB assay61,62 is an ELISPOT
assay, whereas Quantiferon Gold63 is an ELISA test.
Both ELISPOT64,65 and the whole blood interferon-
gamma ELISA66 have shown in outbreak investiga-
tions that M. tuberculosis exposure is more strongly
associated with RD-1 specific antigen based assays
than with TST. Recently, an attempt has been made
to estimate the likelihood of latent TB infection by
calculating a contact score that quantified expo-
sure to the index case. The likelihood of a positive
interferon-gamma assay increased significantly
with a rising contact score.67 Most studies using
intensity of exposure as a surrogate measure to
predict latent TB infection were conducted in
developed countries. However, studies in countries
with high prevalence of TB showed that accuracy of
interferon-gamma assays in predicting latent TB
infection was not as good as that observed in low
prevalence countries.28,68,69
Assays based on RD1-specific antigens have
shown to cause less confounding by BCG vaccina-
tion than TSTand are therefore more reliable to use
in BCG vaccinated individuals.59,64–67,69–71 ELISPOT
has shown improved accuracy over TST in children
with suspected TB who are of young age, mal-
nourished and those with HIV infection. Interferon-
gamma assays might also improve diagnostic
accuracy in latently infected people with greatest
risk of progression in whom TST is often false-
negative especially people with HIV infection.72
Their superiority in patients who are on immuno-
suppressive medication is unclear since indetermi-
nate interferon-gamma results limit their clinical
usefulness.73–75 In haemodialysis patients, ESAT-6
has been shown to be unaffected by uraemia-
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a better marker of LTBI than TST.41 Nevertheless,
very few studies have been published on the use of
these assays in HIV-infected individuals, patients on
immunosuppressive medications, and those with
other immunocompromising conditions. Thus there
is lack of evidence to recommend RD-1 specific
antigen based assays in immunosuppressed patients
at the moment.
There is a lot of heterogeneity in the interferon-
gamma assays with regard to antigens, format, type
and source of antigens, cut-off points used for
positivity, type of blood specimen use, and incuba-
tion period. There are several technical issues,
including impact of specimen collection, storage,
transport and time from collection to incubation.
Unexplained high background interferon-gamma
response and indeterminate results especially in
immunosuppressed patients have also been re-
ported.74,75 The repeatability of the interferon-
gamma assay results over time in the same
individual is largely unknown. Inter-laboratory
variability is also poorly studied. A new interfer-
on-gamma assay based on ESAT-6 and CFP-10 fusion
protein has become available in addition to that
based on peptides of these antigens.76 Whether it is
preferable to conduct the interferon-gamma assay
with recombinant protein or pools of peptides, or
whether increased sensitivity could be achieved
through measurement of a combined peptide and
protein response, needs to be established.77Future direction
More research and development is needed to
determine the efficacy of the new tests in detect-
ing latent TB in both developed and developing
countries. There is a need to determine whether
high responses to RD-1 specific antigens predict a
higher risk of developing active TB. Assays using
additional antigens apart from ESAT-6 and CFP-10
need to be evaluated.28,78 There is a need to
discover more specific antigens which do not cross
react with non-tuberculous mycobacteria. Recom-
binant proteins of existing antigens77 (in addition to
their peptide pools), should be evaluated further.
Studies comparing performance of the ELISA and
ELISPOT assay will have to be done.
Current interferon-gamma assays based on RD-1
specific antigen assays have shown improved
performance over both PPD-based assays and TST.
Despite the expense involved, they may be cost-
effective as they may reduce unnecessary chemo-
prophylaxis and use of health care resources
associated with false results. They have thepotential to lessen the number of active TB cases,
if they prove to be more accurate than TST. In the
future, longitudinal studies of the association
between interferon-gamma response and subse-
quent risk of development of active TB will allow us
to determine whether or not these tests are
superior to TST.
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Search strategy and selection criteria
Electronic searches of MEDLINE (from 1966
to present), EMBASE (from 1980 to present)
were undertaken to identify citation of studies
comparing interferon-gamma assays with tu-
berculin skin test and those providing diag-
nostic information on the value of these tests
in latent tuberculosis infection. Experts in the
field were contacted and manufacturers’
websites were visited. Reference lists of all
relevant reviews and primary articles were
searched. There were no language restrictions
in the search or selection process.
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